Removal of 239Pu from mice with 3,4,3 LICAM(C) or N,N',N'',N'''-tetra-(2,3-dihydroxybenzoyl)-spermine.
Male mice SAS/4 were injected i.v. with 239Pu citr(IV) 0.27 microCi . kg-1-9.99 kBq X kg-1. After 1 h 30 mumol . kg-1 of 3,4,3 LICAM(C), N,N',N'',N'''-tetra-(2,3-dihydroxybenzoyl)-spermine or Na3CaDTPA as a reference compound was given intraperitoneally. After 4 days the animals were sacrificed and the Pu content in livers, kidneys, femurs and carcasses was determined by the liquid scintillation method. It was found that, as compared with the control, 3,4,3 LICAM(C) removed 83% of the Pu activity deposited in the liver, 71% of that in the femur and 79% of the Pu in the whole body. The Pu content in the kidneys exceeded the control value by about 50%. Na3CaDTPA removed 96, 86, 40 and 72% of plutonium from the liver, kidneys, femurs and carcasses respectively. Tetra-DHB-spermine caused the excretion of 50, 57 and 39% of Pu from liver, bone and whole body respectively. The retention of Pu in the kidneys was increased to 400% of the control value.
D000818:Animals; D001842:Bone and Bones / Q000378:metabolism; D002614:Chelating Agents / Q000494:pharmacology*; D005269:Femur / Q000378:metabolism; D007668:Kidney / Q000378:metabolism; D007700:Kinetics; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D004369:Pentetic Acid / Q000494:pharmacology; D011005:Plutonium / Q000302:isolation & purification / Q000378:metabolism*; D013095:Spermidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D013096:Spermine / Q000031:analogs & derivatives* / Q000494:pharmacology; D013329:Structure-Activity Relationship; D014018:Tissue Distribution
D002614:Chelating Agents; D013096:Spermine; D011005:Plutonium; C049295:N,N',N'',N'''-tetra(2,3-dihydroxybenzoyl)spermine; C034834:LICAM-C; D004369:Pentetic Acid; D013095:Spermidine